An 80% decrease in hospital admissions for infants with respiratory syncytial virus (RSV) chest infections has been attributed to a pregnancy vaccine, according to health authorities.
Over 20,000 babies were estimated to require hospitalization after contracting RSV, a condition that primarily affects newborns and can lead to breathing difficulties and feeding challenges.
Since 2024, pregnant women have been offered a vaccine starting at 28 weeks to lower the incidence of RSV in newborns. An analysis of the vaccine’s impact revealed by the UK Health Security Agency (UKHSA) indicated significant protection for vulnerable infants.
RSV is a major cause of hospital admissions for babies under one year old. The NHS notes that infants under six months, premature babies, elderly individuals over 75, and those with weakened immune systems are at higher risk.
Nearly all children contract RSV before age two, with severe cases requiring hospital care due to breathing issues.
Dr. Conall Watson, the RSV program lead at UKHSA, expressed concern, stating that parental fear over RSV is justified. The study showed an approximate 85% protection rate for newborns when the vaccine is administered at least four weeks before birth.
The research also revealed that administering the vaccine closer to birth could still offer some protection, with Dr. Watson advising pregnant women to receive the vaccine throughout the third trimester if necessary.
Statistics from the study, which examined around 300,000 births in England from September 2024 to March of the following year, showed that the majority of hospitalized babies had not been vaccinated against RSV.
A mother, Laine Lewis, shared the story of her son Malachi, who suffered brain damage from RSV as a baby. While rare, she emphasized the importance of RSV vaccination for child safety.
Dr. Watson emphasized the vaccine’s potential to safeguard babies during winter months and encouraged pregnant women to discuss vaccination with healthcare providers and receive it as recommended.
In England, approximately 64% of pregnant women receive the RSV vaccine, with a lower uptake of 53% in London.